Sentences with phrase «lung cancer drug tarceva»

Genentech's lung cancer drug Alecensa received FDA's conditional approval for the treatment of ALK - positive lung cancer.

Eli Lilly takes a win over generic challenger Actavis as London court rules in its favor in a patent case involving lung cancer drug Alimta.

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana - Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors» constant and varied molecular shape - shifting.

The lung cancer drug — called gefitinib — helps by blocking a protein that is known to encourage cell growth, and which was found to be present in high levels at the site of ectopic pregnancies.

Women with ectopic pregnancies could be spared surgery if they are treated with a lung cancer drug, a study suggests.

The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients.

Tamara Minko and colleagues at Rutgers University in New Jersey decided to encapsulate the lung cancer drug doxorubicin in fatty bubbles that are small and light enough to be inhaled.

Rep. Brian Higgins on Friday called on the Trump administration to avoid policy changes that would endanger Roswell Park Cancer Institute's work on a promising lung cancer drug developed in Cuba.

Rep. Brian Higgins called on the Trump administration to avoid policy changes that would endanger Roswell Park Cancer Institute's work on a promising lung cancer drug developed in Cuba.

HERERA: Merck (NYSE: MRK) was one of the best performing stocks on the blue chip Dow index today, after the drug company «s new type of lung cancer drug performed better than expected in a highly anticipated clinical trial.

The timing of the news report alarmed investors, coming as the company waits for all - important data from a lung cancer drug trial which is seen as a game - changer for Astra.

said they will discontinue a late - stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.

PACKAGING lung cancer drugs in inhalable bubbles could allow bigger doses to be delivered to tumours without the side effects associated with chemotherapy.

Cancer Institute of NJ Investigates Promising Immunotherapy for Toughest Lung Cancers Drug Discovery & Development — May 14, 2015

Waco How Chip Joanna Gaines are renovating Wacos reputation, one home time medical speed - dating study will lung cancer drugs patients.

Not exact matches

Darzalex, however, has not yet reached its peak potential as the drug moves into earlier stages of the disease and is being tested on solid tumours like lung cancer.

The Hong Kong - listed company has two blockbuster drugs on its roster — anlotinib for lung cancer and tenofovir for hepatitis B — and a few blockbuster generics aiming for approval before 2021.

Analysts at the investment bank said the Dow member's sales could boom because of Keytruda, a blockbuster drug used to treat lung cancer.

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

Since then, the companies have been scrambling to rack up indications for the rival drugs, which are both approved for treating melanoma and lung cancer.

The drug had $ 942 million in global 2015 sales (versus $ 566 million for Keytruda) and, according to the company, has been prescribed to 60 % of new lung cancer patients.

The company actually beat Wall Street profit estimates largely thanks to its superstar cancer immunotherapy drug Keytruda, which has been shown to best chemotherapy in helping lung cancer patients live longer and given Merck a leg up over rivals like Bristol - Myers Squibb's immune therapy Opdivo.

That medicine made by drug giant Merck (NYSE: MRK) showed some new results today in lung cancer that are being called unprecedented.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.

Celgene will help fund a study with BeiGene's lung cancer hopeful, tislelizumab, and in return pay BeiGene royalties on any U.S. sales of the drug.

Delivering cancer drugs directly to the lungs is the obvious answer, but how?

A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SClung cancer (cancer (SCLC).

Other trials of this drug target in lung cancer have not worked, and the drugs» effects in colorectal cancer are also questionable, Stambolic says.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

«Immunotherapy drug improves survival for common form of lung cancer.»

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arcancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, ArCancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Colon cancer requires different drug regimens than lung, breast, or skin cancer.

«Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe.»

«Blood pressure drug may boost effectiveness of lung cancer treatment.»

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

Whereas most conventional scientists focus on a single system or disease, Butte earned tenure recently with a dossier of advances in diabetes, obesity, and transplant rejection, and the discovery of new drugs for lung cancer and other diseases.

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

A one - two combo punch using two currently available drugs could be an effective treatment for the majority of lung cancers, a study by scientists with UT Southwestern's Simmons Cancer Center shows.

Both drugs are approved for treating metastatic melanoma, and Opdivo is also approved for squamous lung cancer.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

A blood pressure drug may make a type of lung cancer treatment more effective, suggests a new study.

The scientists identified several, including the investigational cancer drug BEZ235, which blocked a key metabolic pathway in flu - infected human lung epithelial cells.

Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the drug giant Novartis, the trial also found fewer cases of lung cancer in those on the treatment, rekindling basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.

«Our study results suggest a new drug cocktail that is effective in both human lung cancer cell lines and fly models,» says Cagan.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sidrug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount SiDrug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sidrug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.